Duration of hospitalization results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project
-
Median duration was 12 days for DEX group, 13 for control
-
Probability of discharge within 28-day followup was higher for DEX than controls (RR 1.11, 95% CI (1.04, 1.19), p=0.002)
-
Greatest effect in those with mechanical ventilation (test for trend p=0.002)
-
summarized in Table 2 child node
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
28-day mortality results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project
Table 1 from study evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
Table 2 from study evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
Figure 1 for 28-day mortality results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project
Figure 2. for 28-day mortality results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project
Duration of hospitalization results in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in the UK RECOVERY project